EGFR and cancer: By now, most EGFR-TKIs aim to target the biological functions of EGFR caused by kinase activation, and to induce cytotoxicity of cancer cells, yet drug-resistant mutations, together with changes in the stability of EGFR still limits the use and efficacy of EGFR-TKIs in clinical practice.